- Tomlinson, IPM;
- Dunlop, M;
- Campbell, H;
- Zanke, B;
- Gallinger, S;
- Hudson, T;
- Koessler, T;
- Pharoah, PD;
- Niittymäkix, I;
- Tuupanenx, S;
- Aaltonen, LA;
- Hemminki, K;
- Lindblom, A;
- Försti, A;
- Sieber, O;
- Lipton, L;
- van Wezel, T;
- Morreau, H;
- Wijnen, JT;
- Devilee, P;
- Matsuda, K;
- Nakamura, Y;
- Castellví-Bel, S;
- Ruiz-Ponte, C;
- Castells, A;
- Carracedo, A;
- Ho, JWC;
- Sham, P;
- Hofstra, RMW;
- Vodicka, P;
- Brenner, H;
- Hampe, J;
- Schafmayer, C;
- Tepel, J;
- Schreiber, S;
- Völzke, H;
- Lerch, MM;
- Schmidt, CA;
- Buch, S;
- Moreno, V;
- Villanueva, CM;
- Peterlongo, P;
- Radice, P;
- Echeverry, MM;
- Velez, A;
- Carvajal-Carmona, L;
- Scott, R;
- Penegar, S;
- Broderick, P;
- Tenesa, A;
- Houlston, RS
It is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics) consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT.
